Does the Way You Take Testosterone Change Its Effect on Your Heart?

By Nelson Vergel | B.S. Chemical Engineering, MBA | Founder, ExcelMale.com | 34+ years on TRT | NIH and FDA advisory panel service | Author: Testosterone: A Man's Guide, Beyond Testosterone, The Peptide Consensus | Updated July 2026

ExcelMale Consensus: The route you use to take testosterone affects your cardiovascular risk more than most men realize. Injectable esters like cypionate and enanthate produce hormone peaks well above the normal range, and those peaks drive up hematocrit far more often than gels do. In the HEAT-Registry, 43.8% of men on intramuscular testosterone crossed into abnormal hematocrit territory versus 15.4% on gel. If you have existing heart disease or a baseline hematocrit above 50%, a steady-delivery formulation is the safer starting point, and your blood work is what tells you whether the choice is working.

Most conversations about testosterone and the heart stop at one number: hematocrit. That number matters, but it is downstream of something more interesting. Your arteries have a repair system, and testosterone helps run it. When your level drops, that system slows down. When you replace testosterone, the way you replace it decides whether your blood vessels get steady support or a series of hormonal surges they have to absorb. This article looks at what happens inside the artery wall, why injections and gels send different signals, and what to actually watch on your labs.

Is Low Testosterone Its Own Cardiovascular Risk Factor?​

Yes. Hypogonadism is now treated as an independent cardiovascular risk factor in its own right, well beyond its effect on energy and libido. Low testosterone tracks with endothelial dysfunction and arterial stiffness. It also correlates with chronic low-grade inflammation and a blood environment that clots more easily. A 2024 individual-participant meta-analysis in Annals of Internal Medicine found that men with the lowest testosterone concentrations had higher all-cause mortality, and very low levels were linked to cardiovascular death.

The endothelium is the single-cell lining inside every blood vessel. It controls how vessels dilate, how sticky the walls are to white blood cells, and whether the blood tips toward clotting. Testosterone is one of the hormones that keeps that lining working. When it falls, the lining loses some of its protective capacity before any symptom shows up. That silent phase is why lab markers matter.

What Blood Vessel Markers Tell You That Cholesterol Doesn't?​

A standard lipid panel tells you about circulating fats. It says almost nothing about whether your artery walls are repairing themselves or breaking down. For that, researchers look at two opposing signals.

Endothelial progenitor cells (EPCs) are bone-marrow cells that circulate and home in on damaged spots in the vessel wall, then rebuild the lining. Think of them as the repair crew. Hypogonadal men have measurably fewer of them in circulation. Testosterone helps mobilize this crew through the CXCL12/CXCR4 signaling pathway and by supporting nitric oxide production.

Endothelial microparticles (EMPs) are the opposite signal. These are tiny membrane fragments shed by stressed or dying endothelial cells. High EMP counts mean the lining is actively being damaged, and the fragments themselves carry pro-clotting cargo. Low testosterone raises them.

The worst-case profile is low EPCs alongside high EMPs: no repair capacity and active damage at the same time. This pattern shows up often in men who have both metabolic dysfunction and low testosterone. Restoring testosterone shifts the balance back toward repair in most men, though the size of that shift varies.

One honest caveat: EPC measurement is not standardized across labs. Different centers use different surface markers to identify these cells, so a single absolute count means less than a trend over time. Treat these as research-grade markers that explain mechanism, not as something to order at your next visit.

How Does Testosterone Actually Reach the Artery Wall?​

Testosterone works on blood vessels through a fast pathway and a slow one. The slow, genomic pathway involves testosterone binding androgen receptors inside the cell and changing which genes get expressed over hours to days. The fast, non-genomic pathway happens in seconds to minutes at the cell membrane.

The fast pathway is where most of the vascular benefit lives. Testosterone activates Src kinase and the PI3K/Akt cascade, which phosphorylates the enzyme eNOS at a site called Ser1177. Activated eNOS produces nitric oxide. Nitric oxide relaxes the vessel to lower blood pressure and keeps platelets from clumping. It also reduces the wall stickiness that lets plaque get a foothold. This activation happens independent of testosterone converting to estradiol, which means testosterone itself drives the effect.

Testosterone also lowers asymmetric dimethylarginine (ADMA), a molecule that blocks nitric oxide production. Hypogonadal men run high on ADMA. Clearing it is part of how testosterone restores healthy dilation.

Why Does Injection vs. Gel Change the Cardiovascular Picture?​

Because the two methods produce completely different hormone curves, and your blood vessels respond to the shape of that curve as much as to the average level.

Short-acting intramuscular esters like cypionate and enanthate create a sharp peak within a day or two of the shot, often pushing well above the normal range, followed by a drop toward a trough before the next dose. Transdermal gels deliver a steady daily level that tracks closer to the body's natural rhythm.

That difference is not cosmetic. Supraphysiological peaks flip testosterone from a vascular protector into a vascular stressor. At those high concentrations, testosterone stimulates NADPH oxidase and mitochondrial reactive oxygen species, and it activates the NLRP3 inflammasome, a molecular alarm that triggers inflammatory cytokine release inside the vessel wall. Steady levels keep eNOS phosphorylated and EPC mobilization stable without setting off that alarm.

Feature	Transdermal Gel	Short-Acting IM Injection
Delivery pattern	Steady, near-circadian	Peak then trough
Typical testosterone range	Stable, physiological	Supraphysiological peak, then sub-normal
Effect on eNOS / nitric oxide	Sustained support	Oscillating
Erythrocytosis risk	Lower (15.4% in HEAT)	Higher (43.8% in HEAT)
Abnormal hematocrit driver	Minimal	Peaks stimulate EPO, suppress hepcidin

Long-acting testosterone undecanoate sits between these two. It avoids the sharp weekly swings of short esters but does not match the daily stability of a gel. Some men also split short-ester doses into smaller, more frequent injections to flatten the peaks, which is a common ExcelMale strategy for keeping hematocrit down without switching formulations.

Why Do Injections Raise Hematocrit More Than Gels?​

Testosterone drives red blood cell production through two levers. It increases erythropoietin (EPO) output from the kidneys, and it suppresses hepcidin, the liver hormone that limits how much iron reaches the bone marrow. With hepcidin low, iron flows freely to make more red cells. A 2010 study in The Journal of Clinical Endocrinology & Metabolism identified this hepcidin suppression as a core mechanism.

The peaks from injections push both levers harder than the steady level from a gel. Higher hematocrit means thicker, more viscous blood, which the heart has to work harder to move through small vessels. Above 54%, most guidelines call for action. This rise in viscosity is one reason improved lab markers on TRT do not automatically translate into fewer heart attacks: the thickening can offset some of the benefit from better nitric oxide signaling.

Do Better Blood Markers Mean a Lower Risk of Heart Attack?​

Not necessarily, and this is the part that gets oversold. TRT reliably improves surrogate markers. It raises EPCs and lowers ADMA. It improves insulin sensitivity and often nudges cholesterol in a favorable direction. Cleaner labs feel reassuring. They are not the same as proof of fewer cardiac events.

The TRAVERSE trial, published in The New England Journal of Medicine in 2023, followed 5,246 men at high cardiovascular risk. Transdermal testosterone was non-inferior to placebo for the combined endpoint of cardiovascular death, nonfatal heart attack, and nonfatal stroke. That is genuinely reassuring for the major events. TRAVERSE also flagged higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group, so "non-inferior for MACE" does not mean "no cardiovascular signals at all."

There is a second wrinkle. A substudy of the Testosterone Trials, published in JAMA in 2017, found that testosterone treatment was associated with greater progression of non-calcified coronary plaque volume in men 65 and older, even while their metabolic markers improved. Non-calcified plaque is the softer, more rupture-prone kind. Better surrogate numbers and more soft plaque showed up in the same population.

The takeaway is not that TRT is dangerous. It is that biomarker improvement and hard-outcome safety are two separate questions, and only the second one is settled by randomized trials with pre-specified endpoints. TRT earns "mechanistic reassurance," and for major events TRAVERSE adds real evidence, but neither one is a promise of cardiovascular immunity.

How Should a Man on TRT Monitor His Heart Safety?​

Target a total testosterone in the mid-normal range, roughly 400 to 700 ng/dL, rather than chasing the top of the range. Higher is not better here, and the peaks that come with pushing levels up are exactly what stress the vasculature.

Check hematocrit at baseline, again at 3 to 6 months, then annually. If it climbs above 54%, the dose needs to come down, the formulation may need to change, or therapeutic phlebotomy comes into play. If your baseline hematocrit is already above 50%, a gel is the more forgiving starting point.

Track blood pressure, a lipid panel, and fasting glucose or HbA1c at least yearly. Report shortness of breath, chest pain, or new leg swelling promptly, since those can signal a clot or fluid problem. And treat TRT as a complement to the basics that move cardiovascular risk on their own: losing visceral fat, training regularly, and sleeping enough all raise testosterone and protect the heart independent of any prescription.

For men with a recent heart attack or stroke, most guidance advises waiting 3 to 6 months before starting TRT until things are stable. Severe, poorly controlled heart failure is generally a reason to hold off entirely.

Frequently Asked Questions​

Is gel or injection safer for the heart?​

For cardiovascular safety, gels have the edge on paper because they avoid supraphysiological peaks and cause abnormal hematocrit far less often (15.4% vs 43.8% in the HEAT-Registry). That said, no head-to-head trial has compared them on hard endpoints like heart attack, so this is a pharmacokinetic and hematologic advantage, not proven mortality benefit.

What hematocrit level is dangerous on TRT?​

Most guidelines flag action at 54%. Above that, blood viscosity rises enough to raise clot risk, and the standard response is dose reduction, a formulation change, or therapeutic phlebotomy. Isolated readings can be thrown off by dehydration, so decisions should rest on repeated measurements.

Does testosterone cause heart attacks?​

The TRAVERSE trial found transdermal testosterone non-inferior to placebo for major cardiac events in high-risk men. Most of the heart-attack risk historically tied to TRT comes from unmonitored high hematocrit, which is why regular blood testing matters more than the therapy itself.

Can TRT improve my blood vessel function?​

In most men, yes, at the level of markers. Testosterone increases nitric oxide, lowers ADMA, and mobilizes endothelial repair cells. Whether that translates to fewer real-world cardiac events is a separate question that surrogate markers cannot answer.

Why does my hematocrit go up more on injections than gel?​

Injection peaks push red blood cell production harder by raising erythropoietin and suppressing hepcidin, which frees up iron for red cell synthesis. The steadier level from a gel applies less of that stimulus, so hematocrit tends to stay lower.

The One Thing Most Men Miss About TRT and Heart Health​

Here is something that rarely makes it into a doctor's visit: the peak matters more than the average. Two men can have the same monthly average testosterone, one on a daily gel and one on a weekly injection, and their blood vessels see two very different environments. The injection guy's arteries ride a wave up into stress territory and back down every week. If your hematocrit keeps creeping up despite a "normal" testosterone level, the shape of your dosing curve is the first place to look, not the dose alone. Splitting your injections into smaller, more frequent shots, or moving to a cream, is often all it takes.

If you want to go deeper on the hematocrit side of this, start with our guide to lowering high hematocrit on TRT and the member success stories thread.

Related ExcelMale Forum Discussions​

• TRT and Cardiovascular Disease - Member discussion and study abstracts on the TRAVERSE trial and CV safety data.
• How to Lower High Hematocrit Caused by TRT - Nelson's practical guide to managing elevated hematocrit on testosterone.
• Managing TRT-Induced High Hematocrit: Success Stories - Real member experiences with dose and donation strategies.
• Could Rusfertide Help Men on TRT with High Hematocrit? - The hepcidin connection and an emerging drug approach.
• TRT Side Effects: Complete Guide to Managing Them - Full rundown of side effects including hematocrit and blood pressure.
• How to Lower Red Blood Cell Count and Hematocrit While on Testosterone - Mechanisms and management options for erythrocytosis.
• Transdermal vs. Injections of Testosterone - Long-running thread on the pros and cons of each delivery method.
• New TRT User Frustrated on 1.62% Gel - Discussion touching on transdermal cardiovascular safety and DHT.
• Testosterone Injection Frequency and Its Effect on Hematocrit - Members compare dosing schedules and their effect on blood thickness.

Key References​

1. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine. 2023. https://doi.org/10.1056/NEJMoa2215025
2. Yeap BB, et al. Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men. Annals of Internal Medicine. 2024. https://doi.org/10.7326/M23-2781
3. Budoff MJ, et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017. https://doi.org/10.1001/jama.2016.21043
4. Corona G, et al. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men. The Aging Male. 2022. https://doi.org/10.1080/13685538.2022.2063830
5. Bachman E, et al. Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced Erythrocytosis. The Journal of Clinical Endocrinology & Metabolism. 2010. https://doi.org/10.1210/jc.2010-0864
6. Corona G, et al. Cardiovascular disease and testosterone therapy in male hypogonadism. Annals of the New York Academy of Sciences. 2024. https://doi.org/10.1111/nyas.15211
7. Francomano D, et al. Acute endothelial response to testosterone gel administration in men with severe hypogonadism and its relationship to androgen receptor polymorphism: a pilot study. Journal of Endocrinological Investigation. 2015. https://doi.org/10.1007/s40618-015-0325-4
8. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2018. https://doi.org/10.1210/jc.2018-00229

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or modifying any hormone therapy or medical treatment.

About ExcelMale​

ExcelMale.com is a men's health community with more than 24,000 members and over 20 years of archived discussions on testosterone replacement, hormone optimization, and related topics. It was founded by Nelson Vergel, author of Testosterone: A Man's Guide and Beyond Testosterone, and draws on decades of patient advocacy and clinical collaboration to give men evidence-based, peer-supported information.

 

Thread 'How Does Testosterone Therapy Affect Your Cholesterol and Lipid Profile?'

May 19, 2026

Curated By Nelson Vergel | ExcelMale.com | Updated May 2026
Meta Title: How TRT Affects Your Cholesterol and Lipid Profile
Meta Description: Learn how testosterone replacement therapy affects HDL, LDL, triglycerides, and Lp(a). What TRT men need to monitor for heart health.

Key Takeaways

• Therapeutic TRT doses (equivalent to 100-150 mg/week) cause minimal or no reduction in HDL cholesterol; large drops are mainly seen with AAS abuse or supraphysiological doses....

• Nelson Vergel
• TRT Cholesterol trt hdl trt heart TRT LDL TRT Lipids TRT Lpa TRT Triglycerides
• Replies: 2
• Forum: Testosterone Side Effect Management

 

Heart Health & Testosterone: A Guide to Vascular Markers and Mechanisms​

1. Introduction: The Vascular Landscape and Testosterone's Role​

In the field of vascular biology, hypogonadism (testosterone deficiency) is increasingly recognized as more than a simple hormonal deficit; it is an independent cardiovascular risk factor. While historically viewed through the lens of sexual health, testosterone is actually a critical regulator of the heart's "inner lining"—the endothelium. When testosterone levels fall, this delicate lining loses its protective capacity, fundamentally altering the vascular landscape.
The primary cardiovascular risks associated with low testosterone include:

• Endothelial Dysfunction: The inability of blood vessels to dilate and contract appropriately in response to blood flow.
• Arterial Stiffness: A decrease in vessel elasticity that contributes to hypertension and cardiac strain.
• Chronic Inflammation: The activation of pathways that promote atherosclerotic plaque development.
• Prothrombotic States: A heightened tendency for blood to form dangerous clots within the vessels.

To truly assess a patient’s status, we must look beyond traditional cholesterol panels and use specific circulating biomarkers to "peek inside" the health and repair capacity of these blood vessels.

2. The Heroes of Repair: Endothelial Progenitor Cells (EPCs)​

Endothelial Progenitor Cells (EPCs) represent the body's "mobile repair crew." Originating in the bone marrow, these cells are released into circulation to home in on sites of vascular injury. Once they reach a damaged area, they regenerate the vessel lining and maintain vascular homeostasis.
In clinical monitoring, we identify these cells by specific phenotypes/markers that tell us about their maturity and intent:

Phenotype / Surface Markers	Learning Insight
CD34+, CD133+	These identify the cell as a "stem cell" or progenitor with the potential for tissue regeneration.
KDR / VEGFR-2	The "Endothelial Marker" indicating the cell is destined for a vascular role.
CD144 (VE-cadherin)	A critical marker indicating the cell is ready to incorporate into the actual structural wall of the vessel.

In hypogonadal states, the bone marrow’s ability to mobilize this repair crew is impaired. This deficit in regeneration allows "damage signals" to dominate the vascular environment.

3. The Signals of Stress: Endothelial Microparticles (EMPs)​

If EPCs are the repair crew, Endothelial Microparticles (EMPs) are the "alarm bells" or the "smoke" indicating a vascular fire. These are small membrane vesicles (0.1–1.0 µm) released by endothelial cells during periods of high stress, activation, or cell death (apoptosis).
The danger of EMPs lies in their cargo: they carry pro-inflammatory and pro-thrombotic molecules that facilitate the sticking of white blood cells to the vessel walls and the formation of clots.
The Diabetic/Vascular Paradox: The highest cardiovascular risk profile occurs when a patient exhibits the "Diabetic/Vascular Paradox"—the combination of low EPCs (no repair capacity) and high EMPs (active, ongoing damage). This is frequently observed in patients with concurrent metabolic dysfunction and hypogonadism.

Contrast: The Repair Crew vs. The Damage Markers​

• EPCs (The Repair Crew): High levels indicate a robust ability to fix the vascular lining.
• EMPs (The Damage Markers): High levels indicate the endothelial lining is actively being stripped or damaged by inflammatory stress.

The balance between these two players is governed by the molecular engine powered by testosterone.

4. The Molecular Engine: How Testosterone Powers Vascular Health​

Testosterone protects the heart by driving the production of Nitric Oxide (NO) via the PI3K/Akt/eNOS signaling pathway. This occurs through a rapid, "Non-Genomic" action that does not require the slower process of gene transcription.

The Learning Path: The NO Engine​

1. Binding: Testosterone binds to the Androgen Receptor (AR) on the cell membrane.
2. Activation: This triggers the rapid response of the Src kinase and PI3K/Akt pathways.
3. Phosphorylation: These signals activate the enzyme eNOS (Endothelial Nitric Oxide Synthase). Clinical Pearl: This activation occurs independent of aromatization to estradiol, meaning testosterone itself is the primary driver.
4. Production: The activated eNOS produces Nitric Oxide (NO).

Benefit Box: Why is Nitric Oxide the "Hero Molecule"? Nitric Oxide is the master protector of the vasculature. Its benefits include:

• Vasodilation: Relaxing vessels to maintain healthy blood pressure.
• Anti-Platelet: Preventing blood cells from clumping into clots.
• Anti-Inflammatory: Reducing the "stickiness" of the vessel walls to prevent plaque buildup.

When this engine fails, clinicians often look toward Testosterone Replacement Therapy (TRT) to restore function.

5. Comparing TRT Formulations: Transdermal vs. Intramuscular​

The method of testosterone delivery—the "pharmacokinetic curve"—is a critical factor in vascular safety. We must contrast the steady delivery of transdermal gels against the fluctuating levels of traditional intramuscular injections.

Category	Transdermal Gel (Steady-State)	Intramuscular Injection (Bolus)
Testosterone Levels	Consistent physiological levels.	Supraphysiological peaks followed by sub-physiological troughs.
EPC/EMP Response	Stable mobilization and repair.	Oscillating levels; potential for transient endothelial stress.
Vascular Markers	Reduced ADMA (an eNOS inhibitor).	↑PDMPs (Platelet-derived microparticles/thrombotic risk).
Erythrocytosis Risk	Lower; normal hematocrit (<54%).	Higher; risk of "thick blood" and inflammation.

The Erythrocytosis Risk​

Intramuscular injections, due to their supraphysiological peaks, can overstimulate red blood cell production. If hematocrit exceeds 54%, the blood becomes viscous (thick), which significantly increases the risk of thrombotic events. Stable delivery via gels minimizes this specific vascular stressor.

6. Clinical Monitoring and The "Surrogate" Warning​

Effective management requires a consistent monitoring schedule to ensure the therapy stays within the physiological safety window.

Learner’s Summary Checklist​

• [ ] Total Testosterone: Target the mid-normal range (400–700 ng/dL) during therapy. (Schedule: Baseline, 3-6 months, Annually)
• [ ] Hematocrit: Ensure levels stay below 54% to prevent viscosity-related clots. (Schedule: Baseline, 3-6 months, Annually)
• [ ] hsCRP (High-Sensitivity C-Reactive Protein): Monitor for systemic inflammation. Note: Inflammatory response to TRT can be heterogeneous; many trials show no significant change in CRP. (Schedule: Baseline, 6 months, Annually)
• [ ] Blood Pressure: Monitor to ensure the "Nitric Oxide engine" is maintaining vessel relaxation. (Schedule: Every visit)

A Critical Distinction: Biomarkers like EPCs and EMPs are "surrogate endpoints." While their improvement is a positive sign of cellular health, it does not always guarantee a reduction in heart attacks. For instance, the TRAVERSE trial established "non-inferiority" (TRT did not cause more major cardiac events), but the Shaikh et al. study noted that TRT may be associated with the progression of non-calcified coronary plaque—the type of plaque most vulnerable to rupture.

7. Conclusion: The Balanced View​

The "So What?" for clinical practice is clear: Testosterone is a vital fuel for the heart’s repair systems, capable of restoring the "repair crew" (EPCs) and silencing "damage signals" (EMPs). However, the formulation is paramount.
Maintaining steady, physiological levels through transdermal delivery avoids the "peaks and valleys" of injections that can trigger erythrocytosis and vascular stress. Heart health in the context of TRT is not a "set it and forget it" intervention; it requires personalized medicine, diligent biomarker monitoring, and a foundational commitment to lifestyle health.

 

Clinical Evidence Review: Reconciling Molecular Biomarkers and Clinical Endpoints in Testosterone Replacement Therapy (TRT)​

1. Introduction: The Surrogate-to-Outcome Gap in Andrology​

In contemporary andrology, a critical strategic imperative exists to distinguish between molecular improvements in surrogate markers and reductions in Major Adverse Cardiovascular Events (MACE). While hypogonadism is established as an independent cardiovascular risk factor—associated with endothelial dysfunction, pro-thrombotic states, and systemic inflammation—the restoration of physiological testosterone levels does not always yield a linear reduction in hard clinical endpoints. The objective of this review is to synthesize the molecular architecture of androgen action with the clinical outcome reality established by landmark trials. By reconciling the mechanistic data regarding circulating biomarkers with the clinical findings of the TRAVERSE trial and the Testosterone Trials, we can establish a framework for evidence-based decision-making that prioritizes patient safety alongside physiological optimization.

2. Molecular Architecture of Testosterone Action​

Predicting vascular responses to Testosterone Replacement Therapy (TRT) requires a sophisticated understanding of the dual nature of androgen signaling. Testosterone modulates vascular tone and integrity through genomic and non-genomic pathways, creating a complex intracellular environment that is generally considered "atheroprotective" at physiological concentrations.

• Genomic Pathways: These classical mechanisms involve testosterone or dihydrotestosterone (DHT) binding to intracellular androgen receptors (AR), resulting in AR dimerization, nuclear translocation, and the transcriptional regulation of target genes. A primary outcome of this pathway is the increased expression of endothelial nitric oxide synthase (eNOS).
• Non-Genomic Pathways: These rapid actions are mediated by membrane-associated receptors and signaling cascades such as the Src kinase-PI3K/Akt-eNOS pathway. Within minutes, this cascade triggers the phosphorylation of eNOS at the Ser1177 site, facilitating immediate nitric oxide (NO) production. Additionally, testosterone modulates ion channels (L-type calcium and ATP-sensitive potassium channels) to induce rapid vasodilation.

Critically, the activation of the CXCL12/CXCR4 axis and the PI3K/Akt pathway promotes an environment that inhibits leukocyte adhesion and prevents vascular smooth muscle cell proliferation. This molecular foundation provides the "mechanistic reassurance" that underpins the clinical use of TRT.

3. Circulating Biomarkers: Indicators of Vascular Repair and Damage​

The circulating balance between Endothelial Progenitor Cells (EPCs) and Endothelial Microparticles (EMPs) serves as a sensitive repair-to-damage proxy for vascular health. In hypogonadal men, this ratio is typically skewed toward a pro-apoptotic and pro-thrombotic state.
Vascular Health Indicators in Hypogonadism

Biomarker Type	Direction in Hypogonadism	Clinical Impact
Endothelial Progenitor Cells (EPCs)	Decreased (↓)	Impaired vascular repair and neovascularization.
Endothelial Microparticles (EMPs)	Elevated (↑)	Marker of endothelial apoptosis and pro-thrombotic cargo.
Endothelin-1 (ET-1)	Elevated (↑)	Potent vasoconstriction and endothelial dysfunction.
von Willebrand Factor (vWF)	Elevated (↑)	Increased platelet adhesion and pro-thrombotic risk.
Asymmetric Dimethylarginine (ADMA)	Elevated (↑)	Endogenous eNOS inhibitor; reduced NO bioavailability.
Inflammatory Markers (IL-6, TNF-α)	Elevated (↑)	Systemic inflammation and atherosclerotic progression.

Synthesis of Cellular and Enzymatic Markers​

The mobilization of EPCs is a hallmark of TRT-mediated vascular repair, driven by the upregulation of Vascular Endothelial Growth Factor (VEGF) and the CXCL12/CXCR4 axis. Conversely, elevated EMP levels in hypogonadal states signal ongoing endothelial injury. A critical enzymatic mechanism involved in restoring endothelial health is the enhancement of DDAH activity by testosterone, which reduces concentrations of ADMA, thereby removing a significant brake on eNOS function. While platelet markers show increased reactivity in specific cohorts (e.g., Klinefelter syndrome as noted by Minno et al.), neutral findings in larger longitudinal studies (Chang et al.) suggest that thrombotic risk is often tied to supraphysiological dosing rather than physiological replacement.

4. The "So What?" Layer: Reconciling Biomarkers with Clinical Outcome Trials​

A central tension persists in andrology: "surrogate success" does not always equate to clinical benefit. This "Biomarker-Outcome Paradox" highlights that while molecular signals may improve, systemic risks can remain or even increase depending on the clinical context.
The Biomarker-Outcome Paradox

1. MACE Non-Inferiority and Adverse Signals: The TRAVERSE Trial demonstrated that TRT is non-inferior to placebo for MACE (MI, stroke, CV death) in high-risk men. However, the trial identified increased incidences of atrial fibrillation, acute kidney injury, and pulmonary embolism. This suggests that improved vascular biomarkers do not eliminate specific systemic risks.
2. Plaque Progression vs. Metabolic Improvement: In the Testosterone Trials substudy (Shaikh et al.), TRT was associated with a greater progression of non-calcified coronary plaque volume despite improvements in metabolic markers such as insulin sensitivity and cholesterol. Furthermore, Mohler et al. observed a disconnect where TRT improved surrogate metabolic factors but failed to significantly reduce hard inflammatory markers like IL-6 or hsCRP.
3. The Erythrocytosis Counter-Weight: The lack of hard-endpoint improvement, despite better NO production, may be explained by testosterone-induced erythrocytosis. Testosterone stimulates renal erythropoietin (EPO) production and suppresses hepcidin, leading to increased hematocrit. This rise in blood viscosity can counteract the "atheroprotective" effects of PI3K/Akt activation.

5. Formulation Dynamics: Transdermal vs. Intramuscular (IM) Delivery​

The pharmacokinetic rationale for formulation choice is paramount in cardiovascularly vulnerable populations. The delivery method dictates whether a patient experiences stable physiological restoration or risky supraphysiological fluctuations.

• Steady-State Kinetics: Transdermal gels provide uniform testosterone levels that support sustained eNOS phosphorylation at Ser1177 and stable EPC mobilization. This mimics the natural circadian rhythm and avoids the inflammatory surges associated with peak-and-trough kinetics.
• Supraphysiological Peaks: Short-acting intramuscular (IM) esters (e.g., enanthate or cypionate) create high initial peaks followed by hypogonadal troughs. These peaks are linked to increased oxidative stress, NLRP3 inflammasome activation, and transient endothelial stress. Long-acting options like testosterone undecanoate (TU) offer an intermediate risk profile but lack the daily stability of transdermals.

Hematological Risk Profile Data from the HEAT-Registry and Dobs et al. confirm a stark disparity in safety: intramuscular formulations are associated with a 43.8% rate of abnormal hematocrit elevation (>54%), compared to only 15.4% for transdermal delivery. This significantly higher rate of erythrocytosis in IM initiators—particularly with short-acting esters—is a primary driver of increased viscosity and potential thrombotic events.

6. Clinical Application: Monitoring and Risk Mitigation​

To bridge the gap between molecular theory and patient safety, a standardized monitoring framework must be employed, adhering to Endocrine Society guidelines.

• Baseline Assessments:
  • Confirmation of hypogonadism via two separate morning total testosterone measurements.
  • Comprehensive cardiovascular screening and baseline hematocrit assessment.
  • Contraindication: TRT should not be initiated in men who have experienced a recent cardiovascular event (myocardial infarction or stroke) within the previous 3–6 months.
• The 3–6 Month Window:
  • Titrate dosage to achieve testosterone targets of 400–700 ng/dL.
  • Assess hematocrit; if levels exceed 54%, therapy must be interrupted or the dose reduced.
• Long-term Surveillance:
  • Annual monitoring of blood pressure, lipids, and glucose.
  • Vigilant reporting of symptomatic changes (dyspnea, chest pain, or leg swelling).

7. Conclusion: A Balanced Perspective on TRT Cardiovascular Safety​

The current landscape of TRT and cardiovascular health is characterized by "mechanistic reassurance" rather than "proven clinical benefit." TRT effectively restores beneficial molecular pathways—specifically the Src-PI3K/Akt-eNOS (Ser1177) cascade—and improves surrogate biomarkers like EPC counts and ADMA levels. However, these improvements must not be interpreted as evidence of mortality reduction or total cardiovascular immunity.
The transdermal route is pharmacokinetically preferred due to its superior stability and significantly lower risk of erythrocytosis compared to short-acting IM esters. While surrogate markers suggest a healthier vascular environment, hard-endpoint data from randomized controlled trials remain the gold standard for clinical claims. TRT should be utilized to improve quality of life and physiological markers, provided it is managed within a rigorous monitoring framework that respects the limits of current clinical evidence.